Why Is SIBN Stock Dropping Today? SI-BONE Falls After Q2 Earnings Despite Raised Guidance

SI-BONE (SIBN) shares fell 10. 29% in after-hours trading Monday after the medical device company reported second-quarter results that paired a 15.2% revenue increase and raised full-year guidance with a GAAP net loss. Investors appeared to focus on the bottom-line shortfall, sending the stock lower despite an otherwise improving financial picture.

What Did SI-BONE Report?

SI-BONE posted second-quarter revenue of $56.0 million, a 15.2% increase from the prior-year period. The company also reached a milestone, reporting its first quarter of positive adjusted EBITDA since going public.

The company has been working to broaden adoption of its iFuse implant system for sacroiliac joint dysfunction, and the revenue growth suggests those efforts are gaining traction. Management raised full-year 2026 revenue guidance to a range of $231 million to $233 million, signaling confidence that second-half demand will build on the first half's momentum.

Those headline figures, however, came with a caveat. SI-BONE reported a GAAP net loss of $4.1 million, or $0.09 per diluted share. The gap between adjusted EBITDA profitability and the GAAP bottom line may reflect ongoing investments in R&D, stock-based compensation, and commercialization spending as the company works to expand its surgeon base. The GAAP loss introduced a note of caution into an otherwise improving report.

Why Did Investors React?

The sell-off after a largely positive release points to a "sell the news" dynamic. The stock may have entered the print with elevated expectations, and the GAAP loss gave traders a specific reason to lock in gains.

The first quarter of positive adjusted EBITDA is a genuine inflection point. It means that before non-cash charges and one-time items, SI-BONE's underlying business is now generating positive earnings. The raised full-year revenue guidance of $231 million to $233 million reinforces the demand picture.

In a normal session, an earnings report with double-digit revenue growth, an EBITDA milestone, and raised guidance might have been received positively.

But the GAAP net loss of $4.1 million means SI-BONE has not yet reached fully reported profitability. In a market environment where investors are increasingly distinguishing between adjusted and GAAP results, that gap carried disproportionate weight in the after-hours session.

After-hours trading adds a mechanical layer to the move. Liquidity in the post-market session is significantly thinner than during regular hours, meaning a relatively modest volume of sell orders can drive an outsized price swing. Volume indicators from Monday's after-hours session were weak, suggesting limited participation and raising the possibility that the decline overstates the breadth of negative sentiment.

What Comes Next?

The regular trading session on Tuesday will be the first opportunity to see whether institutional investors share the after-hours reaction or view the raised guidance and adjusted-EBITDA progress as reasons to step in. If the guidance raise and revenue momentum resonate with a broader set of market participants, the stock could reclaim some or all of the after-hours decline.

Management's earnings call commentary will be closely scrutinized. The central question is the timeline for converting positive adjusted EBITDA into GAAP net income. Investors will be listening for details on the operating costs keeping the bottom line in the red and whether management sees a clear path to closing the profitability gap this fiscal year.

Analyst model revisions in the days following the report could also shift the stock's direction. The raised guidance range of $231 million to $233 million sits above prior expectations, and upward estimate revisions could provide a counterweight to the initial after-hours selling. The quarter delivered several positive signals that the 10.29% drop may prove to be an overreaction tied to thin-session conditions — but the coming days will determine whether investors ultimately weigh the raised outlook above the GAAP bottom-line gap.